WO2009087467A3 - Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases - Google Patents

Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases Download PDF

Info

Publication number
WO2009087467A3
WO2009087467A3 PCT/IB2008/003651 IB2008003651W WO2009087467A3 WO 2009087467 A3 WO2009087467 A3 WO 2009087467A3 IB 2008003651 W IB2008003651 W IB 2008003651W WO 2009087467 A3 WO2009087467 A3 WO 2009087467A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
binding fragments
receptor
diseases
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/003651
Other languages
French (fr)
Other versions
WO2009087467A2 (en
Inventor
Karl Hofbauer
Jean Christophe Peter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Basel
Original Assignee
Universitaet Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Basel filed Critical Universitaet Basel
Priority to US12/811,249 priority Critical patent/US8252908B2/en
Priority to EP08869649.7A priority patent/EP2227490B1/en
Priority to JP2010540187A priority patent/JP5685774B2/en
Publication of WO2009087467A2 publication Critical patent/WO2009087467A2/en
Publication of WO2009087467A3 publication Critical patent/WO2009087467A3/en
Anticipated expiration legal-status Critical
Priority to US13/560,638 priority patent/US8703139B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are monoclonal antibodies, binding fragments, and derivatives thereof directed to the human melanocortin-4 receptor, as well as pharmaceutical compositions including the same, and therapeutic uses, including methods for treating cachexia and related conditions and diseases, using such monoclonal antibodies, binding fragments, derivatives, and pharmaceutical compositions.
PCT/IB2008/003651 2007-12-31 2008-12-30 Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases Ceased WO2009087467A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/811,249 US8252908B2 (en) 2007-12-31 2008-12-30 Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases
EP08869649.7A EP2227490B1 (en) 2007-12-31 2008-12-30 Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases
JP2010540187A JP5685774B2 (en) 2007-12-31 2008-12-30 Monoclonal antibodies against melanocortin-4 receptor and binding fragments thereof and their use in the treatment of cachexia and related medical conditions and diseases
US13/560,638 US8703139B2 (en) 2007-12-31 2012-07-27 Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1836007P 2007-12-31 2007-12-31
US61/018,360 2007-12-31
US2966108P 2008-02-19 2008-02-19
US61/029,661 2008-02-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/811,249 A-371-Of-International US8252908B2 (en) 2007-12-31 2008-12-30 Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases
US13/560,638 Division US8703139B2 (en) 2007-12-31 2012-07-27 Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases

Publications (2)

Publication Number Publication Date
WO2009087467A2 WO2009087467A2 (en) 2009-07-16
WO2009087467A3 true WO2009087467A3 (en) 2009-12-17

Family

ID=40637117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/003651 Ceased WO2009087467A2 (en) 2007-12-31 2008-12-30 Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases

Country Status (6)

Country Link
US (2) US8252908B2 (en)
EP (1) EP2227490B1 (en)
JP (1) JP5685774B2 (en)
AU (1) AU2008200795A1 (en)
CA (1) CA2619381A1 (en)
WO (1) WO2009087467A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100022442A1 (en) * 2008-07-25 2010-01-28 Ambryx Biotechnology, Inc. Compositions and methods for increasing serum antioxidant concentrations, decreasing serum triglyceride levels, inhibiting insulin-receptor signaling activity, increasing serum ghrelin levels, and decreasing serum tnf-alpha levels
BR112019009485A2 (en) * 2016-12-09 2019-07-30 Fujifilm Corp mixed mode affinity chromatography vehicle
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
US20240400659A1 (en) * 2021-10-19 2024-12-05 Bioatla, Inc. Conditionally active proteins for neurodegenerative diseases
CN116731184B (en) * 2022-11-25 2024-06-14 厦门康基生物科技有限公司 Monoclonal antibody F6H12 specifically binding to Taq enzyme and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703220A (en) * 1994-02-17 1997-12-30 The Regents Of The University Of Michigan Genes encoding melanocertin-4 receptor and methods of use
WO2000027863A1 (en) * 1998-11-09 2000-05-18 Merck & Co., Inc. Dna molecules encoding the melanocortin 4 receptor protein from rhesus monkey
EP1167386A1 (en) * 2000-06-26 2002-01-02 Pfizer Products Inc. Canine and feline melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287763B1 (en) * 1996-06-10 2001-09-11 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US5908609A (en) * 1996-06-10 1999-06-01 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
KR100427645B1 (en) * 2001-07-24 2004-04-28 한국생명공학연구원 Human melanocortin-4 receptor specific antibody and the preparation method thereof
AU2008200794A1 (en) * 2007-12-31 2009-07-16 University Of Basel Methods for diagnosing and treating obesity by modulating the activity of auto-antibodies against the melanocortin-4 receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703220A (en) * 1994-02-17 1997-12-30 The Regents Of The University Of Michigan Genes encoding melanocertin-4 receptor and methods of use
WO2000027863A1 (en) * 1998-11-09 2000-05-18 Merck & Co., Inc. Dna molecules encoding the melanocortin 4 receptor protein from rhesus monkey
EP1167386A1 (en) * 2000-06-26 2002-01-02 Pfizer Products Inc. Canine and feline melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FOSTER A C ET AL: "Melanocortin-4 receptor antagonists as potential therapeutics in the treatment of cachexia", CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 7, no. 11, 1 June 2007 (2007-06-01), pages 1131 - 1136, XP002474509, ISSN: 1568-0266 *
HOFBAUER K G ET AL: "Antibodies as pharmacologic tools for studies on the regulation of energy balance", NUTRITION, ELSEVIER INC, US, vol. 24, no. 9, 1 September 2008 (2008-09-01), pages 791 - 797, XP024099250, ISSN: 0899-9007, [retrieved on 20080726] *
NICHOLSON J R ET AL: "Melanocortin-4 receptor activation stimulates hypothalamic brain-derived neurotrophic factor release to regulate food intake, body temperature and cardiovascular function", JOURNAL OF NEUROENDOCRINOLOGY, vol. 19, no. 12, December 2007 (2007-12-01), pages 974 - 982, XP002529240, ISSN: 0953-8194 *
PETER JEAN-CHRISTOPHE ET AL: "Antibodies against the melanocortin-4 receptor act as inverse agonists in vitro and in vivo", AMERICAN JOURNAL OF PHYSIOLOGY - REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, vol. 292, no. 6, June 2007 (2007-06-01), pages R2151 - R2158, XP002529239, ISSN: 0363-6119 *

Also Published As

Publication number Publication date
WO2009087467A2 (en) 2009-07-16
JP2011508739A (en) 2011-03-17
US8252908B2 (en) 2012-08-28
CA2619381A1 (en) 2009-06-30
US8703139B2 (en) 2014-04-22
AU2008200795A1 (en) 2009-07-16
EP2227490A2 (en) 2010-09-15
US20110044987A1 (en) 2011-02-24
JP5685774B2 (en) 2015-03-18
EP2227490B1 (en) 2016-05-11
US20130058941A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
WO2009020933A3 (en) Therapeutic use of anti-tweak receptor antibodies
WO2010066803A3 (en) Human antibodies against human tissue factor
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2011160119A3 (en) Anti-gd2 antibodies
WO2007109747A3 (en) Methods and compositions for antagonism of rage
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
EP4183806A3 (en) Glycan-interacting compounds and methods of use
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
EP3539988A3 (en) Monoclonal antibodies against her2
WO2005103081A3 (en) Human monoclonal antibodies against cd20
MX2009008787A (en) 2-aminopyrimidine modulators of the histamine h4 receptor.
WO2009061996A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
IL189972A0 (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2008085794A3 (en) Methods and compositions related to clot binding compounds
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
WO2008076278A3 (en) Methods of cancer treatment with igf1r inhibitors
WO2008027739A3 (en) Antibodies to ntb-a
WO2006058868A3 (en) Substituted pteridines for treating inflammatory diseases
MX2012006430A (en) Combination preparations comprising a cytokine antagonist and corticosteroid.
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2009051957A3 (en) Antibodies to irem-1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08869649

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008869649

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010540187

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12811249

Country of ref document: US